These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

888 related items for PubMed ID: 19602890

  • 1. Excessive Daytime sleepiness in idiopathic restless legs syndrome: characteristics and evolution under dopaminergic treatment.
    Kallweit U, Siccoli MM, Poryazova R, Werth E, Bassetti CL.
    Eur Neurol; 2009; 62(3):176-9. PubMed ID: 19602890
    [Abstract] [Full Text] [Related]

  • 2. Outcome of restless legs severity after continuous positive air pressure (CPAP) treatment in patients affected by the association of RLS and obstructive sleep apneas.
    Delgado Rodrigues RN, Alvim de Abreu E Silva Rodrigues AA, Pratesi R, Krieger J.
    Sleep Med; 2006 Apr; 7(3):235-9. PubMed ID: 16564217
    [Abstract] [Full Text] [Related]

  • 3. Dopaminergic treatment in idiopathic restless legs syndrome: effects on subjective sleepiness.
    Kallweit U, Khatami R, Pizza F, Mathis J, Bassetti CL.
    Clin Neuropharmacol; 2010 Apr; 33(6):276-8. PubMed ID: 21060282
    [Abstract] [Full Text] [Related]

  • 4. Sudden onset of sleep and dopaminergic therapy in patients with restless legs syndrome.
    Möller JC, Körner Y, Cassel W, Meindorfner C, Krüger HP, Oertel WH, Stiasny-Kolster K.
    Sleep Med; 2006 Jun; 7(4):333-9. PubMed ID: 16554184
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Open-label study of the long-term efficacy and safety of pramipexole in patients with Restless Legs Syndrome (extension of the PRELUDE study).
    Partinen M, Hirvonen K, Jama L, Alakuijala A, Hublin C, Tamminen I, Koester J, Reess J.
    Sleep Med; 2008 Jul; 9(5):537-41. PubMed ID: 18276187
    [Abstract] [Full Text] [Related]

  • 9. Is daytime sleepiness a neglected problem in patients with restless legs syndrome?
    Fulda S, Wetter TC.
    Mov Disord; 2007 Jul; 22 Suppl 18():S409-13. PubMed ID: 17588232
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Acute placebo-controlled sleep laboratory studies and clinical follow-up with pramipexole in restless legs syndrome.
    Saletu M, Anderer P, Saletu-Zyhlarz G, Hauer C, Saletu B.
    Eur Arch Psychiatry Clin Neurosci; 2002 Aug; 252(4):185-94. PubMed ID: 12242580
    [Abstract] [Full Text] [Related]

  • 12. Successful treatment of recalcitrant restless legs syndrome with botulinum toxin type-A.
    Rotenberg JS, Canard K, Difazio M.
    J Clin Sleep Med; 2006 Jul 15; 2(3):275-8. PubMed ID: 17561538
    [Abstract] [Full Text] [Related]

  • 13. Where dopamine meets opioids: a meta-analysis of the placebo effect in restless legs syndrome treatment studies.
    Fulda S, Wetter TC.
    Brain; 2008 Apr 15; 131(Pt 4):902-17. PubMed ID: 17932100
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Clinical characteristics of restless legs syndrome in end-stage renal failure and idiopathic RLS patients.
    Enomoto M, Inoue Y, Namba K, Munezawa T, Matsuura M.
    Mov Disord; 2008 Apr 30; 23(6):811-6; quiz 926. PubMed ID: 18074382
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Rating scales for inattention and sleepiness are correlated in adults with symptoms of sleep disordered breathing syndrome, but not in adults with symptoms of attention-deficit/hyperactivity disorder.
    Sangal RB, Sangal JM.
    Sleep Med; 2004 Mar 30; 5(2):133-5. PubMed ID: 15033132
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Efficacy and safety of pramipexole in idiopathic restless legs syndrome: a polysomnographic dose-finding study--the PRELUDE study.
    Partinen M, Hirvonen K, Jama L, Alakuijala A, Hublin C, Tamminen I, Koester J, Reess J.
    Sleep Med; 2006 Aug 30; 7(5):407-17. PubMed ID: 16815748
    [Abstract] [Full Text] [Related]

  • 20. Predictors of impaired daytime sleep and wakefulness in patients with Parkinson disease treated with older (ergot) vs newer (nonergot) dopamine agonists.
    Razmy A, Lang AE, Shapiro CM.
    Arch Neurol; 2004 Jan 30; 61(1):97-102. PubMed ID: 14732626
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 45.